What are the precautions for taking dacomitinib/dacomitinib?

DacomitinibIt is used to treat a certain type of non-small cell lung cancer that has spread to other parts of the body. Dacomitinib/Dacomitinib(Dacomitinib)Belongs to the kinase inhibitor class of drugs, It works by blocking the activity of an abnormal protein that sends a reproduction signal to cancer cells, This helps slow or prevent the spread of cancer cells.

1. Interstitial lung disease (ILD). Severe and fatal ILD/pneumonitis occurred in 394 patients who received Dacominib in 0.5% of patients treated with Visionox; 0.3% of cases were fatal. Monitor patients for the development of pulmonary symptoms of ILD/pneumonia. If a patient develops worsening of respiratory symptoms (e.g., dyspnea, cough, and fever) that may be indicative of ILD, dacomitinib should be discontinued and the patient should be investigated for ILD immediately. If ILD is confirmed, permanently discontinue dacomitinib.

2.Diarrhea. Patients receivingdacomitinib/dacomitinib developed severe and fatal diarrhea. For diarrhea of Grade 2 or more severity, withhold dacomitinib/dacomitinib until recovery to less than or equal to Grade 1 severity , then continue dacomitinib at the same or reduced dose depending on the severity of the diarrhea. Immediately initiate anti-diarrheal treatment for diarrhea (loperamide or diphenoxylate hydrochloride and atropine sulfate).

3.Skin adverse reactions. AcceptDacomitinib/DacomitinibTreated patients developed rash and exfoliative skin reactions. Discontinue dacomitinib/2 or any grade grade 3 or grade 4 an>Dacomitinib until recovery to less than or equal to Grade 1 severity, and then continue to use Dacomitinib/Dacomitinib at the same or reduced dose based on the severity of the skin adverse reaction. The incidence and severity of rashes and exfoliative skin reactions may increase with sun exposure. When starting dacomitinib/dacomitinib, begin using a moisturizer and take appropriate steps to limit sun exposure. When Grade 1 rash occurs, initiate treatment with topical antibiotics and topical steroids. For grade 2 or more severe dermatological adverse reactions, initiate oral antibiotics.

4.Embryo-Fetal toxicity. Based on the results of animal studies and its mechanism of action, taking dacomitinib/dacomitin by pregnant women may cause harm to the fetus. In animal reproduction studies, oral administration of dacomitinib/dacomitinto pregnant rats during organogenesis resulted in an increased incidence of post-implantation loss and reduced fetal weight, resulting in exposures approaching the 45mg human dose. EGFRThe lack of signaling has been shown to cause embryonic and postnatal death in animals. Inform pregnant women of potential risks to the fetus. Advise females of childbearing potential to use effective contraception during treatment with dacomitinib and for at least 17 days after the last dose. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0